APTUS BIOSCIENCES LLC

Medtech · Private

Diagnostic biomarker test to distinguish sepsis from non-infectious inflammation and guide antibiotic therapy

Grants
$1.3M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Diagnostic aptamer reagents to develop multi-analyte blood test for pre-clinical, mild and moderate Alzheimer's disease$445,554
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Rapid affordable aptamer-based diagnostic test for Hepatitis C virus$501,200
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Sepsis diagnosis using chemically modified DNA aptamers$356,500
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1165LATDE DIAGNOSTICS CORP.——
1166AUTHENTAG LLC——
1167Logiq.ai Inc.—$1.5M
1168APTUS BIOSCIENCES LLC——
1169Optilume Stricture, LLC—$954K
1170Instanosis, Inc.——
1171OSCILLOSCAPE, LLC—$165K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.